Back to top
more

Tonix Pharmaceuticals (TNXP)

(Delayed Data from NSDQ)

$0.16 USD

0.16
951,912

0.00 (2.04%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.16 0.00 (0.00%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Tonix Pharmaceuticals Holding Corp. [TNXP]

Reports for Purchase

Showing records 101 - 120 ( 154 total )

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 101

02/18/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 102

02/17/2015

Company Report

Pages: 7

Cash Fortified - Reiterate Buy Based on Multiple Catalysts

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 103

01/26/2015

Company Report

Pages: 6

Diversifying R-D Pipeline

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 104

01/26/2015

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 105

01/07/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 106

01/06/2015

Company Report

Pages: 4

Visibility Increasing on TNX-102 SL - Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 107

11/12/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 108

11/12/2014

Company Report

Pages: 8

3Q14 Recap - FDA Clarity Could Emerge in 1Q15

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 109

11/10/2014

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 110

10/30/2014

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 111

10/29/2014

Company Report

Pages: 4

Analyst Day Confirms Bullish Thesis

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 112

09/29/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 113

09/29/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 114

09/29/2014

Company Report

Pages: 7

What Now? Maintain Buy, PT to $10

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 115

09/29/2014

Daily Note

Pages: 4

TNX-102 SL Shows Activity, but Misses Primary Endpoint - First Take

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 116

09/29/2014

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 117

08/11/2014

Company Report

Pages: 8

2Q14 Recap - Focus on BESTFIT Data in 4Q14

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 118

08/11/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 119

08/11/2014

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 120

06/19/2014

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party